Aslidis Anastasios 4

What Happened
Anastasios Aslidis, a director of Cosmos Health (COSM), was granted 40,000 restricted stock units (RSUs) that vested immediately and converted into 40,000 shares of Common Stock on May 19, 2026. The Form 4 shows acquisition of 40,000 shares at $0.28 per share (total reported value $11,320) and a simultaneous conversion/disposition of a derivative security for 40,000 shares with $0.00 proceeds.

Key Details

• Transaction date: May 19, 2026.
• Grant/acquisition: 40,000 shares at $0.28 per share — total reported value $11,320.
• Conversion/disposition: 40,000 derivative shares converted to common stock (reported $0.00 proceeds).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: RSUs were granted under the Issuer’s 2024 & 2025 Omnibus Incentive Plan and vested on the grant date; transactions reported as exempt under Rule 16b-3 (F1, F2).
• Filing timeliness: Report filed June 11, 2026 — well past the standard two-business-day Form 4 deadline (late filing).

Context
This was a compensation award (RSUs vesting and converting to common shares), not an open-market buy or sale. Such awards are routine forms of director compensation and do not necessarily signal a trading decision. The late Form 4 filing reduces the timeliness of disclosure; while common, late filings can draw regulatory or shareholder scrutiny.